Giggles Puffs | Blue Dream | Cart | 1g

THC-D9: Delta 9 THC is the primary compound found in the resinous glands of a cannabis plant, and is directly responsible for psychoactive effects. It mirrors the body’s naturally occurring cannabinoids and attaches to these receptors to alter and enhance sensory perception. THC can create a feeling of euphoria by enhancing dopamine levels in the brain. The amount of THC in a cannabis product can vary widely based on the method of consumption and the strain at the source of that product. The high that is produced is often enhanced by the “entourage effect” which is a combination of multiple cannabinoids in conjunction with various terpenes and individual body chemistry.

CBC: CBC is a unique cannabinoid and is best known for its ability to bind to the TRPV1 and TRPA1 receptors in the brain which are responsible for pain perception. Topical applications of products high in CBC have also shown promise for the treatment of osteoarthritis symptoms and in the treatment of skin conditions such as acne.

THCV: THCV sets itself apart from its cousin THC with its distinct lack of psychoactive effects. THCV also acts as an allosteric modulator for Delta-9-THC thus reducing its psychoactivity. It has been found to be helpful as an appetite suppressant, neuroprotectant and glycemic control in type 2 diabetics.

CBD: CBD is the second most prevalent cannabinoid and is primarily produced by hemp plants and at lower amounts in cannabis. It works as a phytocannabinoid, or binding agent, that adheres to an individual's endocannabinoid system. Cannabidiol has soared in popularity due to its lack of psychoactive effects. Most users seek CBD for its medicinal properties since it was the first cannabinoid to be approved by the FDA. Its healing properties include an ability to help you relax, reduce irritability and ease restlessness.

CBDA: CBDA is a derivative of CBGA and the precursor to the well known cannabinoid CBD. Over the last decade scientists have found that CBDA has a very similar chemical structure to that of nonsteroidal anti-inflammatory drugs (NSAIDs) and thus has shown promise in treating pain due to inflammation by inhibiting COX-2 receptors in the brain that register pain. CBDA has also been shown to help regulate the over release of serotonin that causes severe nausea and vomiting in patients receiving chemotherapy, and while more thorough research is needed these results are very promising.